Tokyo, Japan — November 1, 2025 — AMS, a Tokyo-based innovator in nuclear medicine platforms, today announced the first international deployment of its BSL-177 system at The Carl Gustav Carus Hospital in Dresden (Universitätsklinikum Carl Gustav Carus Dresden), Germany.

The BSL-177 is an advanced adsorption system developed to enhance the safe and efficient management of radioactive liquid waste generated from therapies using Lutetium-177 (¹⁷⁷Lu) labeled radiopharmaceuticals. These targeted cancer therapies are expanding worldwide, increasing the need for innovative infrastructure solutions that support sustainable nuclear medicine practices.

“This milestone marks not only the first BSL-177 installation outside Japan, but also a major step toward safer, more sustainable nuclear medicine,” said Yuichiro Sugawara, CEO of AMS. “Through our collaboration with The Carl Gustav Carus Hospital in Dresden, we are demonstrating how advanced technology can complement existing, robust waste management systems and help prepare hospitals for the growing clinical use of next-generation radiopharmaceuticals.”

As part of the collaboration, the first adsorption of Lutetium-177 from PSMA patient urine using the BSL-177 system was successfully conducted, marking a significant milestone that validates the system’s clinical performance, safety, and operational reliability under real hospital conditions. The collaboration also extends to the adsorption of Actinium-225 (²²⁵Ac), further demonstrating the system’s capability to address next-generation radiopharmaceuticals.

AMS continues to expand its international collaborations to promote safer and more sustainable nuclear medicine. Additional BSL-177 deployments are now being prepared across Europe and APAC, focusing on regions where the system aligns with local regulatory requirements and environmental standards.

About AMS
AMS is a Tokyo-based innovator in nuclear medicine platforms, specializing in advanced radioactive waste treatment systems and sustainable infrastructure for nuclear medicine facilities. Its flagship product, BSL-177, enables hospitals to safely and efficiently process waste from targeted radionuclide therapies, supporting the global expansion of responsible and sustainable nuclear medicine practices.

Media Contact
AMS Public Relations
Email: info@ams-plan.com
Website:www.ams-plan.com.